MedTrace Logo

Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy

NCT02203682 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-11-17

No results posted yet for this study

Summary

The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 weeks, on patients with mild Thyroid-Associated Ophthalmopathy (TAO).

Conditions

  • Graves Ophthalmopathy
  • Graves Disease
  • Thyroid-associated Ophthalmopathy
  • Thyroid Diseases
  • Endocrine System Diseases
  • Eye Diseases, Hereditary
  • Hyperthyroidism
  • Autoimmune Diseases
  • Immune System Diseases

Interventions

DRUG

Doxycycline hyclate

Tab. Doxycycline 50 mg PO per day for 12 weeks

DRUG

Placebo

Tablet placebo for 12 weeks

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Dan Liang, MD · Zhongsh Ophthalmic Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2022-07-31
Completion
2022-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02203682 on ClinicalTrials.gov